Stockscreener 앱 받기
253.68
1.12%
2.80
시간 외 거래:
253.68
전일 마감가:
$250.88
열려 있는:
$251.92
하루 거래량:
964.32K
Relative Volume:
0.98
시가총액:
$37.05B
수익:
$5.02B
순이익/손실:
$1.31B
주가수익비율:
28.47
EPS:
8.91
순현금흐름:
$1.56B
1주 성능:
+1.74%
1개월 성능:
+2.23%
6개월 성능:
+6.92%
1년 성능:
+18.95%
1일 변동 폭
$251.85
$254.06
1주일 범위
$248.72
$254.06
52주 변동 폭
$179.42
$263.05
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
253.68 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
509.36 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.42 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.40 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
215.82 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-19 | 개시 | Morgan Stanley | Overweight |
| 2025-01-16 | 개시 | Goldman | Buy |
| 2025-01-10 | 개시 | Piper Sandler | Neutral |
| 2024-12-13 | 개시 | Stifel | Hold |
| 2024-09-24 | 개시 | Robert W. Baird | Outperform |
| 2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | 업그레이드 | Needham | Hold → Buy |
| 2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 개시 | UBS | Buy |
| 2023-04-14 | 개시 | Mizuho | Buy |
| 2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
| 2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
| 2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
| 2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
| 2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
| 2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
| 2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-06-22 | 개시 | Robert W. Baird | Neutral |
| 2021-06-21 | 재확인 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
| 2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Needham | Hold → Buy |
| 2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 개시 | CLSA | Underperform |
| 2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Perform |
| 2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
| 2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com
ResMed CEO Sells Shares Worth $2 Million - MarketScreener
ResMed Inc Reports Change in Beneficial Ownership - TipRanks
ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria
ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia
ResMed Inc Director Proposes Sale of Common Shares - TipRanks
Successful Exits - University College Dublin
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Resmed Inc Reports Decrease in CDI Issuance for May 2025 - TipRanks
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed Inc. Officer Files Notice for Proposed Sale of Securities - TipRanks
ResMed’s global general counsel Michael Rider sells $9,994 in shares By Investing.com - Investing.com Nigeria
ResMed’s global general counsel Michael Rider sells $9,994 in shares - Investing.com Australia
Dental Sleep Medicine Market Projected to Witness Massive GrowthResMed Inc., SomnoMed Limited - openPR.com
Citi raises ResMed stock price target to AUD45 citing strong EPS growth - Investing.com Nigeria
Here's why I invested MORE money in ResMed shares last week - MSN
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st
Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia
Equities Analysts Issue Forecasts for ResMed Q1 Earnings - Defense World
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Resmed Inc 주식 (RMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chief Executive Officer |
Jun 09 '25 |
Sale |
251.21 |
8,009 |
2,011,910 |
455,503 |
0.74%
0.10%
자본화:
|
볼륨(24시간):